Before revision: + COVID-19: candidate drug treatments in Phase III–IV trials Drug candidate Description Existing disease approval Trial sponsor(s) Location(s) Expected results Notes,referencesRemdesivirantiviral; adenosine nucleotide analog inhibiting RNA synthesis in coronaviruses investigationalGilead, WHO, INSERM, NIAID China, Japan initially; extended internationally in Global Solidarity and Discovery Trials, and US NIAID ACTT Trial Mid-2020 (Chinese, Japanese trials) selectively provided by Gilead for COVID-19 emergency access; both promising and negative effects reported in April
After revision: 2020.+ COVID-19: candidate drug treatments in Phase III–IV trials Drug candidate Description Existing disease approval Trial sponsor(s) Location(s) Expected results Notes,referencesRemdesivirantiviral; adenosine nucleotide analog inhibiting RNA synthesis in coronaviruses investigationalGilead, WHO, INSERM, NIAID China, Japan initially; extended internationally in Global Solidarity and Discovery Trials, and US NIAID ACTT Trial Mid-2020 (Chinese, Japanese trials) selectively provided by Gilead for COVID-19 emergency access; both promising and negative effects reported in April